The evolving place of incretin-based therapies in type 2 diabetes
Open accessAbstract
Treatment options for type 2 diabetes based on the action of the incretin hormone glucagon-like peptide-1 (GLP-1) were first introduced in 2005. These comprise the injectable GLP-1 receptor agonists solely acting on the GLP-1 receptor on the one hand and orally active dipeptidyl-peptidase inhibitors (DPP-4 inhibitors) raising endogenous GLP-1 and other hormone levels by inhibiting the degrading enzyme DPP-4. In adult medicine, both treatment options are attractive and more commonly used because of their action and safety profile. The incretin-based therapies stimulate insulin secretion and inhibit glucagon secretion in a glucose-dependent manner and carry no intrinsic risk of hypoglycaemia. GLP-1 receptor agonists allow weight loss, whereas DPP-4 inhibitors are weight neutral. This review gives an overview of the mechanism of action and the substances and clinical data available.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
DPP-IV inhibitors delay GLP-1 breakdown from its active to inactive form.
“The first therapy is based on the use of DPP-IV inhibitors to delay GLP-1 breakdown from its active to inactive form.250”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [250]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888 · see citing works
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · see citing works
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · see citing works
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · see citing works
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503 · see citing works
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · see citing works
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129 · see citing works
Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128 · see citing works
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · see citing works
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · see citing works
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · see citing works
Eng, J., Kleinman, W. A., Singh, L., Singh, G., & Raufman, J. P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42531-8 · Cited by 1,000 · see citing works
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848 · see citing works
Marre, M., Shaw, J. E., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M. D., Thi, T. D. L., Colagiuri, S., & on behalf of the LEAD‐1 SU study group (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2009.02666.x · Cited by 814 · see citing works
Heine, R. J., Van Gaal, L. F., Johns, D., Mihm, M. J., Widel, M. H., Brodows, R. G., & for the GWAA Study Group* (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-8-200510180-00006 · Cited by 795 · see citing works
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · see citing works
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · see citing works
Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D. M., & Perfetti, R. (2003) · Endocrinology · doi:10.1210/en.2003-0323 · Cited by 664 · cited 1× · see citing works
“Since GLP-1 has a positive effect on beta cell mass in rodents as well as a beneficial effect on the survival of isolated human islets in cell culture [6, 104, 105], it is imaginable that incretin-based therapies may also be advantageous in type 1 diabetes, possibly in combination with immune therapy.”
BackgroundNauck, M. A., Meininger, G. E., Sheng, D., Terranella, L., Stein, P. P., & Sitagliptin Study 024 Group (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00704.x · Cited by 656 · see citing works
Sokos, G. G., Nikolaidis, L. A., Mankad, S. V., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 654 · see citing works
Nikolaidis, L., Elahi, D., Hentosz, T., Doverspike, A., Huerbin, R., Zourelias, L., Stolarski, C. J., Shen, Y.-T., & Shannon, R. (2004) · Circulation · doi:10.1161/01.cir.0000139339.85840.dd · Cited by 546 · see citing works
Brubaker, P. L., & Drucker, D. J. (2004) · Endocrinology · doi:10.1210/en.2004-0015 · Cited by 539 · see citing works
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510 · see citing works
Herman, G. A., Bergman, A. J., Stevens, C., Kotey, P. N.-A., Yi, B., Zhao, P., Dietrich, B., Golor, G., Schrödter, A., Keymeulen, B., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1009 · Cited by 495 · see citing works
Kim, D. S., MacConell, L., Zhuang, D., Kothare, P. A., TRAUTMANN, M. E., Fineman, M. S., & Taylor, K. (2007) · Diabetes Care · doi:10.2337/dc06-2375 · Cited by 447 · see citing works
Kolterman, O., Kim, D. D. H., Shen, L. Z., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.2.173 · Cited by 434 · see citing works
Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R. G., & TRAUTMANN, M. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0510-2 · Cited by 430 · see citing works
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
Zinman, B., Hoogwerf, B. J., García, S. D., Milton, D. R., Giaconia, J. M., Kim, D. D. H., TRAUTMANN, M. E., & Brodows, R. G. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-7-200704030-00003 · Cited by 422 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006) · Diabetologia · doi:10.1007/s00125-006-0316-2 · Cited by 420 · see citing works
DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., & for the Saxagliptin 014 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1984 · Cited by 416 · see citing works
Bunck, M. C., Diamant, M., Cornér, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M.-R., Smith, U., et al. (2009) · Diabetes Care · doi:10.2337/dc08-1797 · Cited by 388 · see citing works
Fehmann, H. C., & Habener, J. F. (1992) · Endocrinology · doi:10.1210/endo.130.1.1309325 · Cited by 337 · see citing works
Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes · doi:10.2337/diabetes.53.3.654 · Cited by 334 · see citing works
Self-citationCreutzfeldt, W., Kleine, N., Willms, B., Ørskov, C., Holst, J. J., & Nauck, M. A. (1996) · Diabetes Care · doi:10.2337/diacare.19.6.580 · Cited by 328 · see citing works
Dore, D. D., Seeger, J. D., & Chan, K. A. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902820519 · Cited by 324 · see citing works
Zinman, B., Gerich, J. E., Buse, J. B., Lewin, A., Schwartz, S. E., Raskin, P., Hale, P. M., Zdravkovic, M. D., & Blonde, L. (2010) · Diabetes Care · Cited by 290 · see citing works
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
Rosenstock, J., Aguilar-Salinas, C. A., KLEIN, E. J., Nepal, S., List, J. F., Chen, R., & for the CV181-011 Study Investigators (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903178735 · Cited by 288 · see citing works
Nikolaidis, L. A., Elahi, D., Shen, Y.-T., & Shannon, R. P. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00347.2005 · Cited by 274 · see citing works
Scott, R. S., Wu, M., Sanchez, M., & Stein, P. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01246.x · Cited by 260 · see citing works
Barnett, A. H., Burger, J., Johns, D., Brodows, R. G., Kendall, D. M., Roberts, A., & TRAUTMANN, M. E. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.006 · Cited by 240 · see citing works
Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
Chan, J. C. N., Scott, R. S., Ferreira, J. C. A., Sheng, D., Gonzalez, E. J., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., & Williams‐Herman, D. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00914.x · Cited by 238 · see citing works
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J. E. B., Bush, M., Yang, F., Stewart, M. W., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237 · see citing works
Chacra, A. R., Tan, G. H., Apanovitch, A. M., Ravichandran, S., List, J. F., Chen, R., & for the CV181-040 Investigators (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02143.x · Cited by 236 · see citing works
Rosenstock, J., Sankoh, S., & List, J. F. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00876.x · Cited by 234 · see citing works
Vilsbøll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. ‐., Kølendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le‐Thi, T., et al. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02333.x · Cited by 213 · see citing works
Chang, A. M., Jakobsen, G., Sturis, J., Smith, M. J., Bloem, C. J., An, B., Gałecki, A. T., & Halter, J. B. (2003) · Diabetes · doi:10.2337/diabetes.52.7.1786 · Cited by 207 · see citing works
Sturis, J., Gotfredsen, C. F., Rømer, J., Rolin, B. C., Ribel, U., Brand, C. L., Wilken, M., Wassermann, K., Deacon, C. F., Carr, R. D., et al. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705397 · Cited by 203 · see citing works
Courrèges, J. P., Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáňová, I., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02484.x · Cited by 191 · see citing works
Herman, G. A., Bergman, A. J., Liu, F., Stevens, C., Wang, A. Q., Zeng, W., Chen, L., Snyder, K., Hilliard, D. A., Tanen, M. R. L., et al. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006289850 · Cited by 187 · see citing works
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K. B., Mattison, J. A., & Greig, N. H. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 183 · see citing works
Heise, T., Graefe-Mody, E. U., Hüttner, S., Ring, A., Trommeshauser, D., & Dugi, K. A. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01046.x · Cited by 176 · see citing works
Carraro‐Lacroix, L. R., Malnic, G., & Girardi, A. C. C. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00082.2009 · Cited by 163 · see citing works
Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model.
Hirata, K., Kume, S., Araki, S., Sakaguchi, M., Chin-Kanasaki, M., Isshiki, K., Sugimoto, T., Nishiyama, A., Koya, D., Haneda, M., et al. (2009) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2009.01.003 · Cited by 160 · see citing works
Karasik, A., Aschner, P. J., Katzeff, H. L., Davies, M. J., & Stein, P. P. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x261069 · Cited by 155 · see citing works
Molecular Pharmacology of Promiscuous Seven Transmembrane Receptors Sensing Organic Nutrients
Wellendorph, P., Johansen, L. D., & Bräuner‐Osborne, H. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.055244 · Cited by 151 · see citing works
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149 · see citing works
Nikolaidis, L. A., Doverspike, A., Hentosz, T., Zourelias, L., Shen, Y.-T., Elahi, D., & Shannon, R. P. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073890 · Cited by 137 · see citing works
Exenatide and Rare Adverse Events
Cure, P., Pileggi, A., & Alejandro, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707137 · Cited by 134 · see citing works
Pratley, R. E., Reusch, J. E. B., Fleck, P. R., Wilson, C., Mekki, Q. A., & on behalf of the Alogliptin Study 009 Group (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903156111 · Cited by 132 · see citing works
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
Williams‐Herman, D., Round, E., Swern, A. S., Musser, B. J., Davies, M. J., Stein, P. P., Kaufman, K. D., & Amatruda, J. M. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-14 · Cited by 128 · see citing works
Exenatide and rare adverse events.
Ahmad, S. R., & Swann, J. (2008) · PubMed · Cited by 123 · see citing works
Nauck, M. A., Ratner, R. E., Kapitza, C., Berria, R., Boldrin, M. N., & Balena, R. (2009) · Diabetes Care · doi:10.2337/dc08-1961 · Cited by 117 · see citing works
Management of Type 2 Diabetes in Treatment-Naive Elderly Patients
Pratley, R. E., Rosenstock, J., Pi-Sunyer, X., Banerji, M. A., Schweizer, A., Couturier, A., & Dejager, S. (2007) · Diabetes Care · doi:10.2337/dc07-1188 · Cited by 112 · see citing works
Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus
Tahrani, A. A., Piya, M. K., & Barnett, A. H. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0014-9 · Cited by 104 · see citing works
Herman, G. A., Bergman, A. J., Yi, B., Kipnes, M. S., & for the Sitagliptin Study 012 Group (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x132587 · Cited by 95 · see citing works
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 94 · see citing works
Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H., Joost, H., Kellerer, M., Kloos, C., Kunt, T., Nauck, M. A., et al. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1239559 · Cited by 91 · see citing works
Self-citationGarber, A. J., KLEIN, E. J., BRUCE, S. R., Sankoh, S., & Mohideen, P. (2005) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2005.00570.x · Cited by 85 · see citing works
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin
Åhrén, B. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1944 · Cited by 83 · see citing works
Fonseca, V. A., Baron, M. A., Shao, Q., & Dejager, S. (2008) · Hormone and Metabolic Research · doi:10.1055/s-2008-1058090 · Cited by 81 · see citing works
Yang, J., Campitelli, J., Hu, G., Lin, Y., Luo, J. J., & Xue, C. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.040 · Cited by 79 · see citing works
Barnett, A. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.15.2593 · Cited by 79 · see citing works
Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0030-9 · Cited by 78 · see citing works
Gedulin, B. R., Smith, P., Prickett, K. S., Tryon, M. S., Barnhill, S. D., Reynolds, J., Nielsen, L. L., Parkes, D. G., & Young, A. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1795-2 · Cited by 77 · see citing works
Potential of liraglutide in the treatment of patients with type 2 diabetes
Deacon, C. F. (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s4039 · Cited by 75 · see citing works
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
Åhrén, B., & Foley, J. E. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01685.x · Cited by 67 · see citing works
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data
Gallwitz, B. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2006.01196.x · Cited by 63 · see citing works
Self-citationMüssig, K., Öncü, A., Lindauer, P. C., Heininger, A., Aebert, H., Unertl, K. E., Ziemer, G., Häring, H., Gallwitz, B., & Holst, J. J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.06.029 · Cited by 56 · see citing works
Self-citationPratley, R. E. (2008) · PubMed Central · Cited by 52 · see citing works
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 51 · see citing works
New treatments in type 2 diabetes: a focus on the incretin‐based therapies
Barnett, A. H. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03396.x · Cited by 50 · see citing works
Liraglutide: A new treatment for type 2 diabetes
Vilsbøll, T. (2009) · Drugs of today · doi:10.1358/dot.2009.45.2.1336104 · Cited by 50 · see citing works
New combination treatments in the management of diabetes: focus on sitagliptin – metformin
Green, J. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3105 · Cited by 43 · see citing works
McGill, J. B. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1998 · Cited by 42 · see citing works
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Gallwitz, B. (2008) · PubMed · Cited by 39 · see citing works
Self-citationFormulary Forum: Exenatide: A New Option for the Treatment of Type 2 Diabetes
Yoo, B. K., Triller, D. M., & Yoo, D. J. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h060 · Cited by 39 · see citing works
Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits
Nauck, M. A., & Marre, M. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.05.1997 · Cited by 38 · see citing works
Malloy, J. L., Capparelli, E. V., Gottschalk, M. E., Guan, X., Kothare, P. A., & Fineman, M. S. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.04.005 · Cited by 37 · see citing works
Nauck, M. A., Trautman, M., Brodows, R. G., Johns, D., Northrup, J., & Kim, D. (2007) · Diabetologia · doi:10.1007/s00125-007-0680-6 · Cited by 35 · see citing works
Update on Nonautoimmune Diabetes in Children
Zeitler, P. S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0493 · Cited by 30 · see citing works
Barnett, A. H. (2005) · Drugs of today · doi:10.1358/dot.2005.41.9.893704 · Cited by 30 · see citing works
Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
Retterstøl, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903164205 · Cited by 24 · see citing works
Lee, Y., Kwon, M. K., Kang, E. S., Park, Y. M., Choi, S. H., Ahn, C. W., Kim, K., Park, C. W., Soo, B., Kim, S. W., et al. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1153 · Cited by 20 · see citing works
Mest, H.-J. (2006) · PubMed · Cited by 18 · see citing works
Liraglutide: a new treatment for type 2 diabetes
Vilsboll, T. (2009) · Drugs of today · doi:10.1358/dot.2009.45.2.1343904 · Cited by 18 · see citing works
Waldron-Lynch, F., von Herrath, M., & Herold, K. C. (2008) · Novartis Foundation symposium · doi:10.1002/9780470697405.ch14 · Cited by 15 · see citing works
Preclinical pharmacology of the new GLP-1 receptor agonist AVE0010
Werner, U. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.02.022 · Cited by 14 · see citing works
New Potential Adjuncts to Treatment of Children With Type 1 Diabetes Mellitus
Raman, V. S., & Heptulla, R. A. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181975ee4 · Cited by 13 · see citing works
An overview of incretin clinical trials.
Garber, A. J., & Spann, S. J. (2008) · PubMed · Cited by 13 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441 · see citing works
Introduction to diabetes mellitus.
Kaul, K., Tarr, J., Ahmad, S., Kohner, E., & Chibber, R. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5441-0_1 · Cited by 293 · see citing works
Rosenstock, J., Marx, N., Kahn, S. E., Zinman, B., Kastelein, J. J. P., Lachin, J. M., Bluhmki, E., Patel, S. D., Johansen, O.-E., & Woerle, H. J. (2013) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112475102 · Cited by 143 · see citing works
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142 · see citing works
Self-citationStructure and mechanism for recognition of peptide hormones by Class B G-protein-coupled receptors
Pal, K., Melcher, K., & Xu, H. E. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.170 · Cited by 135 · see citing works
Obesity and type 2 diabetes: which patients are at risk?
Garber, A. J. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2011.01536.x · Cited by 108 · see citing works
Thompson, A., & Kanamarlapudi, V. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.015 · Cited by 74 · see citing works
Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease
Panchapakesan, U., Mather, A., & Pollock, C. A. (2012) · Clinical Science · doi:10.1042/cs20120167 · Cited by 58 · see citing works
Clinical therapeutic strategies for early stage of diabetic kidney disease
Kitada, M. (2014) · World Journal of Diabetes · doi:10.4239/wjd.v5.i3.342 · Cited by 57 · see citing works
Recent Advances in Gut Nutrient Chemosensing
Nguyen, C. A., Akiba, Y., & Kaunitz, J. D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803414033 · Cited by 56 · see citing works
Li, X., Wang, C., Liang, R., Sun, F., Shi, Y., Wang, A., Liu, W., Sun, K., & Li, Y. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1513-1 · Cited by 43 · see citing works
Forst, T. M., & Pfützner, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.642863 · Cited by 41 · see citing works
Marino, M. T., Costello, D. G., Baughman, R., Boss, A., Cassidy, J., D'Amico, C., van Marle, S., van Vliet, A., & Richardson, P. C. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.85 · Cited by 36 · see citing works
A quantitative assessment of patient barriers to insulin
Casciano, R., Malangone, E., Ramachandran, A., & Gagliardino, J. J. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02590.x · Cited by 34 · see citing works
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 34 · see citing works
Li, X., Huang, X., Bai, C., Qin, D., Cao, S., Mei, Q., Ye, Y., & Wu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00449 · Cited by 32 · see citing works
Targeting thermogenesis and related pathways in anti-obesity drug discovery
Clapham, J. C., & Arch, J. R. S. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.04.004 · Cited by 29 · see citing works
Thompson, A., & Kanamarlapudi, V. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.06.012 · Cited by 27 · see citing works
Blauschmidt, S., Greither, T., Lampe, K., Köller, S., Kaltwaßer, P., & Behre, H. M. (2017) · Clinical Endocrinology · doi:10.1111/cen.13444 · Cited by 26 · see citing works
Thompson, A., & Kanamarlapudi, V. (2014) · Scientific Reports · doi:10.1038/srep07410 · Cited by 24 · see citing works
The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease
Agrawal, V., Giri, C., & Solomon, R. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150331160534 · Cited by 18 · see citing works
Chowdhury, H. H., Velebit, J., Radić, N., Frančič, V., Kreft, M., & Zorec, R. (2016) · Journal of Diabetes Research · doi:10.1155/2016/7481470 · Cited by 16 · see citing works
Pediatric Health Quality Assessment in Different Regions of Russian Federation
Baybarina, E. N., Aa, B., Namazova-Baranova, L. S., Пискунова, С. Г., Besedina, E. A., Sadovshikova, A. N., Yuldashev, O. R., Mukhortova, S. A., Артемова, И. А., Черников, В. В., et al. (2016) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn688 · Cited by 15 · see citing works
FUNDAMENTAL BASES OF SEARCH OF MEDICINES FOR THERAPY OF A DIABETES MELLITUS TYPE 2
Спасов, А. А., Petrov, V. I., Чепляева, Н. И., & Lenskaya, K. V. (2013) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn.v68i2.548 · Cited by 12 · see citing works
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 11 · see citing works
Garber, A. J. (2011) · PubMed · Cited by 10 · see citing works
Alluri, A. A., Guntupalli, Y., Suvarna, S. S., Prystupa, Y., Khetan, S. P., Vejandla, B., & Swathi, N. L. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0031 · Cited by 8 · see citing works
Incretin-based therapies and cancer risk: a review of recent literature safety data
Scavone, C., Sportiello, L., Rafaniello, C., Fiorentino, S., Cimmaruta, D., Rossi, F., & Capuano, A. (2016) · Diabetes Management · Cited by 3 · see citing works
A Gopal Rao, R. G. (2022) · Journal of Diabetes and Treatment · doi:10.29011/2574-7568.010102 · Cited by 1 · see citing works
Alogliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Milani, J. J. N. A. P. (2011) · Clinical Medicine Reviews in Vascular Health · doi:10.4137/cmrvh.s3318 · Cited by 1 · see citing works
Forst, T., & Pfützner, A. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.69 · Cited by 1 · see citing works
Спасов, А. А., & Чепляева, Н. И. (2014) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s199075081404009x · Cited by 1 · see citing works
Potential of pharmacological modulation of level and activity incretins on diabetes mellitus type 2
Спасов, А. А., & Чепляева, Н. И. (2015) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20156104488 · Cited by 1 · see citing works
Incretin-based therapies and their future in Type 2 diabetes mellitus
Sonnett, T. E., Robinson, J. D., & Bowen, K. A. (2011) · Therapy · doi:10.2217/thy.11.4 · Cited by 1 · see citing works
Exploring the structure, function & regulation of the human glucagon-like peptide-1 receptor
Huang, Y. (2011) · Figshare · Cited by 1 · see citing works
Gemeinsamkeiten und Unterschiede inkretinbasierter Therapien
Gallwitz, B. (2011) · Der Diabetologe · doi:10.1007/s11428-011-0696-x
Self-citationGlucose Control in Critically Ill Children: search for optimal strategies
Verhoeven, J. J. (2010) · EUR Research Repository (Erasmus University Rotterdam)
Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors
Mahaseth, R. (2015) · Journal of Patan Academy of Health Sciences · doi:10.3126/jpahs.v1i1.13015
Rodríguez, J. H., & Puig, M. E. L. (2013)
Yelmate, A. A., Bende, S., Satpute, K., & Sonkamble, M. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10823-4
- Authors
- Gallwitz, B.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Gallwitz, Baptist
- ORCID
- Gallwitz, Baptist
- Venue
- Pediatric Nephrology
- Published
- 2010-02-04
- Volume
- 25
- Issue
- 7
- Pages
- 1207-1217
- ISSN
- 0931-041X (ISSN-L)
- 1432-198X
- PMC
- PMC2874027
- OpenAlex
- W1977574777
- Cited by
- 42
- References
- 105
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2022: 1 · 2021: 1 · 2018: 1 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 6 · 2013: 4 · 2012: 5
- FWCI
- 5.07
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pediatric Nephrology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Keywords
- type 2 diabetes, incretin-based therapy, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon-like peptide-1, insulin secretion, glucagon secretion, weight loss, hypoglycemia risk, mechanism of action
- MeSH terms
- Insulin Secretion, Adolescent, Adult, Animals, Child, Diabetes Mellitus, Type 2, Disease Models, Animal, Glucagon, Humans, Hypoglycemic Agents, Insulin, Dipeptidyl Peptidase 4, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
